On March 2, 2022 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat as part of the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 1:30 p.m. ET (Press release, Supernus, MAR 2, 2022, View Source [SID1234609359]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay will be available for 60 days on the Company’s website following the conference.

On March 2, 2022 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported that management will participate in fireside chats at two upcoming virtual conferences (Press release, Protara Therapeutics, MAR 2, 2022, View Source [SID1234609358]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 42nd Annual Health Care Conference on March 9, 2022 at 9:10am ET
Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022 at 2:00pm ET
A live webcast of the fireside chats can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcasts will be archived on the Company’s website for 90 days following the presentations.

On March 2, 2022 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported its participation in three in-person medical conferences and one virtual investor panel in March (Press release, Scynexis, MAR 2, 2022, View Source [SID1234609356]). Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a live panel discussion on drug development in Women’s Health. Event details can be found below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conferences:

International Society for the Study of Women’s Sexual Health (ISSWSH)
Date: March 3-6, 2022
Location: Dallas
Event Page
Council on Resident Education in Obstetrics and Gynecology (CREOG) & Association of Professors of Gynecology and Obstetrics (APGO) Annual Meeting
Date: March 9-12, 2022
Location: Orlando
Event Page
Academy of Managed Care Pharmacy (AMCP)
Date: March 29- April 1, 2022
Location: Chicago
Event Page
Virtual Investor Panel:

Maxim Group’s Annual Growth Conference
Panel: Women’s Health Virtual Event
Date: March 28, 2022
Location: Virtual
Time: 3:00 p.m. ET
Event Page

On March 2, 2022 Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell renal cancer trials at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting taking place between April 8-13, 2022 in New Orleans, Louisiana (Press release, Aravive, MAR 2, 2022, View Source [SID1234609352]). The abstract presentation at AACR (Free AACR Whitepaper) will be presented virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Title: Exposure-Response Analysis of Batiraxcept and Application to Recommended Phase 2 Dose in Platinum-Resistant Ovarian and Clear Cell Renal Cancers
Abstract Number: 7867
Presentation Type: Remote Poster Presentation
Date: April 8, 2022

On March 2, 2022 Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, reported that company management will participate in two virtual investor conferences in March 2022 (Press release, Shattuck Labs, MAR 2, 2022, View Source [SID1234609351]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Conference: 42nd Annual Cowen Healthcare Conference
Format: Ovarian Cancer Panel Discussion
Presenter: Lini Pandite, MBChB, M.B.A., Shattuck’s Chief Medical Officer
Date: March 9, 2022
Time: 12:50 p.m. ET

Conference: Oppenheimer’s 32nd Annual Healthcare Conference
Format: Corporate Presentation
Presenter: Conor Richardson, Shattuck’s Senior Director of Finance and Investor Relations
Date: March 15, 2022
Time: 3:20 p.m. ET

A live webcast of both presentations will be available on the Events & Presentations section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date.